Advanced Neuromodulation for Selected Chronic Pain
Spinal cord stimulation and intrathecal drug delivery are advanced neuromodulation options for carefully selected patients with severe or persistent chronic pain when appropriate conservative and interventional treatments have not provided adequate relief.
Spinal cord stimulation (SCS) and intrathecal drug delivery are advanced neuromodulation treatments used to manage selected cases of chronic pain. They are generally considered when pain remains significant despite appropriate medication, physical rehabilitation and other interventional treatments.
Spinal cord stimulation uses a small implanted pulse generator connected to leads positioned in the epidural space near the spinal cord. The system delivers controlled electrical stimulation to modulate pain signaling within the nervous system.
Modern spinal cord stimulation systems may use different stimulation patterns, including conventional stimulation, high-frequency stimulation and other waveform-based approaches. The appropriate system depends on the patient's pain pattern, diagnosis, treatment goals and clinical evaluation.
An intrathecal pump, also known as an implantable drug delivery system, delivers medication directly into the cerebrospinal fluid through a catheter placed in the intrathecal space. This can allow selected medications to be delivered at much smaller doses than may be required with systemic administration.
These treatments are not interchangeable. SCS works by neuromodulating pain pathways with electrical stimulation, whereas an intrathecal pump delivers medication directly into the spinal fluid. Careful patient selection, diagnostic evaluation and, when appropriate, a trial treatment are important before permanent implantation.
Your pain diagnosis, medical history, previous treatments, medications, functional limitations and treatment goals are reviewed to determine whether neuromodulation may be appropriate.
The pain specialist determines whether spinal cord stimulation, intrathecal drug delivery or another treatment approach is more appropriate for your condition.
When appropriate, a temporary SCS trial or a carefully planned medication trial may be used to assess response before proceeding with a permanent implant.
If the treatment is appropriate and the trial is successful, the permanent system may be implanted, programmed and monitored through scheduled follow-up care.
Neuromodulation may reduce pain intensity in appropriately selected patients with chronic pain.
Spinal cord stimulation systems can be programmed and adjusted to suit changing treatment needs and patient response.
Intrathecal pumps deliver selected medications directly into the cerebrospinal fluid, allowing very small doses in appropriate patients.
When pain is reduced, some patients may find it easier to participate in rehabilitation and daily activities.
Neuromodulation provides an option for selected patients whose pain remains difficult to manage with conventional approaches.
The device type, stimulation settings or intrathecal medication regimen can be tailored according to the patient's diagnosis and treatment response.
Neuromodulation is generally reserved for carefully selected patients with persistent pain after a thorough evaluation and appropriate conventional treatment.
Your doctor may consider neuromodulation if:
Neuromodulation is not a first-line treatment for most pain conditions. It may be considered for selected patients after appropriate diagnosis, conservative treatment and specialist evaluation.
Spinal cord stimulation may be considered in selected patients with persistent spinal or leg pain following spine surgery when further surgery is not indicated or has not adequately addressed the pain.
Certain chronic nerve-related pain conditions may be evaluated for spinal cord stimulation when conventional treatment has not provided sufficient relief.
Spinal cord stimulation may be considered for selected patients with persistent complex regional pain syndrome after appropriate multidisciplinary management.
Carefully selected patients with severe chronic pain that remains difficult to control may be evaluated for advanced neuromodulation options.
Intrathecal drug delivery may be considered in selected patients with severe cancer-related pain when systemic medication is inadequate or associated with unacceptable effects.
Intrathecal baclofen therapy may be considered for selected patients with severe spasticity that is not adequately controlled with other treatments.
A detailed assessment helps identify the pain generator, previous treatment response, functional limitations and suitability for advanced pain management.
Implantable treatments are considered only when the potential benefits and risks are appropriate for the individual patient.
Treatment planning considers both spinal cord stimulation and targeted intrathecal drug delivery when clinically appropriate.
Implantable therapies require ongoing follow-up, programming, medication management and device monitoring, which are incorporated into the treatment plan.
Implantable pain therapies require careful preparation. Your doctor will assess whether the expected benefits justify the risks and long-term commitment associated with the treatment.
For spinal cord stimulation, a temporary trial may be performed before permanent implantation. Intrathecal pump therapy may also involve a medication trial or other assessment depending on the proposed therapy.
Recovery and long-term care depend on the type of neuromodulation treatment performed. Device implantation requires follow-up to assess pain response, wound healing, device function and treatment settings.
You may be advised to:
Spinal cord stimulation and intrathecal pumps require ongoing management. The device settings or medication regimen may need adjustment over time based on treatment response and clinical needs.
Implantation can cause temporary pain, bruising or discomfort around the surgical sites. As with other implanted devices, infection and bleeding are possible complications.
Spinal cord stimulation may also be associated with lead migration, hardware malfunction, inadequate pain relief, unwanted stimulation sensations or the need for revision procedures.
Intrathecal pumps have additional risks related to the catheter, pump and medication. These may include infection, catheter problems, pump malfunction, medication side effects and complications related to interruption or excessive delivery of medication.
Abrupt interruption of certain intrathecal medications can be medically serious. Patients with an implanted pump require regular monitoring and timely refills.
Neuromodulation does not guarantee complete or permanent pain relief. Treatment response varies between patients and depends on the underlying condition, treatment selection and ongoing care.
Contact your treating doctor promptly if you develop fever, wound redness or drainage, severe new pain, new weakness, significant neurological changes or other concerning symptoms after implantation.
When chronic pain remains difficult to manage despite
appropriate treatment, neuromodulation may offer an
additional option for carefully selected patients.
A specialist evaluation can help determine whether
spinal cord stimulation, intrathecal drug delivery or
another treatment is appropriate for you.
Book an Appointment with Vedant Pain Management Clinic